TY - JOUR
T1 - Chitosan-based advanced materials for docetaxel and paclitaxel delivery
T2 - Recent advances and future directions in cancer theranostics
AU - Ashrafizadeh, Milad
AU - Ahmadi, Zahra
AU - Mohamadi, Neda
AU - Zarrabi, Ali
AU - Abasi, Sara
AU - Dehghannoudeh, Gholamreza
AU - Tamaddondoust, Rosette N.
AU - Khanbabaei, Hashem
AU - Mohammadinejad, Reza
AU - Thakur, Vijay Kumar
N1 - Copyright © 2019 Elsevier B.V. All rights reserved.
PY - 2020/2/15
Y1 - 2020/2/15
N2 - Paclitaxel (PTX) and docetaxel (DTX) are key members of taxanes with high anti-tumor activity against various cancer cells. These chemotherapeutic agents suffer from a number of drawbacks and it seems that low solubility in water is the most important one. Although much effort has been made in improving the bioavailability of PTX and DTX, the low bioavailability and minimal accumulation at tumor sites are still the challenges faced in PTX and DTX therapy. As a consequence, bio-based nanoparticles (NPs) have attracted much attention due to unique properties. Among them, chitosan (CS) is of interest due to its great biocompatibility. CS is a positively charged polysaccharide with the capability of interaction with negatively charged biomolecules. Besides, it can be processed into the sheet, micro/nano-particles, scaffold, and is dissolvable in mildly acidic pH similar to the pH of the tumor microenvironment. Keeping in mind the different applications of CS in the preparation of nanocarriers for delivery of PTX and DTX, in the present review, we demonstrate that how CS functionalized-nanocarriers and CS modification can be beneficial in enhancing the bioavailability of PTX and DTX, targeted delivery at tumor site, image-guided delivery and co-delivery with other anti-tumor drugs or genes.
AB - Paclitaxel (PTX) and docetaxel (DTX) are key members of taxanes with high anti-tumor activity against various cancer cells. These chemotherapeutic agents suffer from a number of drawbacks and it seems that low solubility in water is the most important one. Although much effort has been made in improving the bioavailability of PTX and DTX, the low bioavailability and minimal accumulation at tumor sites are still the challenges faced in PTX and DTX therapy. As a consequence, bio-based nanoparticles (NPs) have attracted much attention due to unique properties. Among them, chitosan (CS) is of interest due to its great biocompatibility. CS is a positively charged polysaccharide with the capability of interaction with negatively charged biomolecules. Besides, it can be processed into the sheet, micro/nano-particles, scaffold, and is dissolvable in mildly acidic pH similar to the pH of the tumor microenvironment. Keeping in mind the different applications of CS in the preparation of nanocarriers for delivery of PTX and DTX, in the present review, we demonstrate that how CS functionalized-nanocarriers and CS modification can be beneficial in enhancing the bioavailability of PTX and DTX, targeted delivery at tumor site, image-guided delivery and co-delivery with other anti-tumor drugs or genes.
KW - Chemotherapy
KW - Chitosan
KW - Delivery
KW - Docetaxel
KW - Nanoparticles
KW - Paclitaxel
UR - http://www.scopus.com/inward/record.url?scp=85077311216&partnerID=8YFLogxK
U2 - 10.1016/j.ijbiomac.2019.12.145
DO - 10.1016/j.ijbiomac.2019.12.145
M3 - Review article
C2 - 31870872
AN - SCOPUS:85077311216
SN - 0141-8130
VL - 145
SP - 282
EP - 300
JO - International Journal of Biological Macromolecules
JF - International Journal of Biological Macromolecules
ER -